APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results